Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 701–800 of 1,001
Elliott, J., Kelly, S., Bai, Z., Liu, W., Skidmore, B., Boucher, M., So, D. Y. F., & Wells, G. A. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.01.021 · Cited by 13
Pepe, M., Biondi‐Zoccai, G., Corcione, N., Nestola, P. L., Ferraro, P., Morello, A., Conte, S., Prati, F., Bianchi, F. P., Bortone, A. S., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.04.015 · Cited by 13
Clinical Implications of “Tailored” Antiplatelet Therapy in Patients With Chronic Total Occlusion
Gregorio, M. G. D., Marcucci, R., Migliorini, A., Gori, A. M., Giusti, B., Vergara, R., Paniccia, R., Carrabba, N., Marchionni, N., & Valenti, R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014676 · Cited by 13
Yamamoto, K., Natsuaki, M., Morimoto, T., Shiomi, H., Watanabe, H., Yamaji, K., Watanabe, H., Kato, T., Saito, N., Andò, K., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1117 · Cited by 13
Adverse events beyond 1 year after percutaneous coronary intervention
Madhavan, M. V., & Stone, G. W. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000792 · Cited by 15
Ueda, Y., Tahara, Y., Itoh, T., Tsujita, K., Sakuma, M., Amano, T., Sato, K., Taniguchi, T., Nishiyama, C., Konno, S., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1308 · Cited by 13
“Plaque disruption and thrombosis is the well-known major cause of acute MI, and the process for the onset of acute MI can be divided into stages: (1) formation of vulnerable plaque, (2) disruption of vulnerable plaque, and (3) formation of occlusive thrombus on the disrupted plaque.”
BackgroundTan, J. W. C., Chew, D. P., Brieger, D. B., Eikelboom, J. W., Montalescot, G., Ako, J., Kim, B., Quek, D. K., Aitken, S., Chow, C. K., et al. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.45 · Cited by 13
Khurshid, S. S., Chen, W., Singer, D. E., Atlas, S. J., Ashburner, J. M., Choi, J., Hur, C., Ellinor, P. T., McManus, D. D., Chhatwal, J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020330 · Cited by 13
Mizutani, K., Nakazawa, G., Yamaguchi, T., Ogawa, M., Okai, T., Yashima, F., Naganuma, T., Yamanaka, F., Tada, N., Takagi, K., et al. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab036 · Cited by 13
Okabe, K., Miura, K., Shima, Y., Ikuta, A., Taguchi, Y., Takahashi, K., Osakada, K., Ohya, M., Kubo, S., Tada, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-21-0901 · Cited by 13
Johnson, N. P., Kirkeeide, R. L., & Gould, K. L. (2015) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2015.06.001 · Cited by 13
FITCHETT, D. H., Goodman, S. G., Leiter, L. A., Lin, P., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., & Langer, A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.03.002 · Cited by 14
Predicting long‐term bleeding after percutaneous coronary intervention
Sharma, P. K., Chhatriwalla, A. K., Cohen, D. J., Jang, J., Baweja, P. S., GOSCH, K. L., Jones, P. G., Bach, R. G., Arnold, S. V., & Spertus, J. A. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26529 · Cited by 13
“Similarly, the DAPT study [19] reported a reduction in ischemic events with DAPT beyond 1 year following PCI, but increased bleeding events as compared with placebo therapy.”
ResultSelf-citationDual antiplatelet therapy duration after drug-eluting stents: how long?
Helft, G. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.07.45 · Cited by 13
Chen, Y., Li, J., Song, Y., Xu, J., Tang, X., Jiang, L., Jiang, P. X., Liu, R., Wang, H., Zhao, X.-Y., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.09.013 · Cited by 13
Hwang, D., Park, K. W., Lee, J. M., Rhee, T., Hong, M., Jang, Y., Valgimigli, M., Colombo, A., Gilard, M., Palmerini, T., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.11.013 · Cited by 14
“On the other hand, the DAPT (Dual Antiplatelet Therapy) trial, the only double blinded comparison of 1-year versus 30-month extended DAPT, showed that extended DAPT significantly reduced the rates of stent thrombosis (ST) and the composite outcome of death, myocardial infarction (MI) and stroke but significantly incre…”
BackgroundResultWu, Y., Yao, Z., Yin, J., Chen, J., Qian, J., Shen, L., Ge, L., & Ge, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6739 · Cited by 13
“Long-term DAPT was associated with lower MACE and thrombosis rates (18,19).”
BackgroundThe Conundrum of Reducing Ischemic and Bleeding Events After PCI
Rao, S. V. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.012 · Cited by 13
Percutaneous Coronary Intervention
Rinfret, S., Baron, S. J., & Cohen, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.04.041 · Cited by 13
Self-citationPiccolo, R., & Windecker, S. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.003587 · Cited by 13
Sarafoff, N., Byrne, R. A., Mehilli, J., Sibbing, D., Kristensen, S. D., Laugwitz, K., Mæng, M., & Kastrati, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1312 · Cited by 13
Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
Mourikis, P., & Polzin, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028775 · Cited by 13
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine
Gragnano, F., Capolongo, A., Terracciano, F., Sio, V. D., Maddaluna, P., Fimiani, F., Moscarella, E., Cesaro, A., Montone, R. A., Bianco, R., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2221851 · Cited by 12
“The risk of ischemic events can be reduced by using intense DAPT regimens instead of clopidogrel-based DAPT [7,8] and by extending DAPT duration instead of switching to aspirin monotherapy [9,10].”
BackgroundChinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 edition)
Chinese College of Cardiovascular Physicians (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000079 · Cited by 12
Andò, G., & Costa, F. (2015) · Advances in Interventional Cardiology · doi:10.5114/pwki.2015.54007 · Cited by 12
“12-month DAPT with thienopyridines in patients treated with drug-eluting stents [17].”
BackgroundEveraert, B., Wykrzykowska, J. J., Koolen, J., van der Harst, P., den Heijer, P., Henriques, J. P. S., van der Schaaf, R. J., de Smet, B. J. G. L., Hofma, S. H., Diletti, R., et al. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-1014-z · Cited by 12
“The Dual Antiplatelet Therapy (DAPT) study demonstrated that in patients who tolerated DAPT after DES implantation for 12 months, without a bleeding complication, DAPT up to 30 months, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cereb…”
BackgroundStrategies for the Prevention of Coronary Artery Disease Complications: Can We Do Better?
Ambrose, J. A., & Najafi, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.04.006 · Cited by 13
Thiele, H., & Jobs, A. (2021) · PubMed · doi:10.1007/s00059-020-05002-1 · Cited by 4
Rodrigues, C., Odutayo, A., Patel, S., Agarwal, A., da Costa, B. R., Lin, E., Yeh, R. W., Jüni, P., Goodman, S. G., Farkouh, M. E., et al. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007903 · Cited by 13
Self-citationLee, P. H., Park, S., Nam, H., Kang, D., Kang, S., Lee, S., Kim, Y., Park, S., & Lee, C. W. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019637 · Cited by 12
Iijima, R., Kadota, K., Nakao, K., Nakagawa, Y., Shite, J., Yokoi, H., Kozuma, K., Tanabe, K., Akasaka, T., Shinke, T., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0717 · Cited by 12
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI
Chiarito, M., Baber, U., Cao, D., Sharma, S. K., Dangas, G., Angiolillo, D. J., Briguori, C., Cohen, D. J., Dudek, D., Džavík, V., et al. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.11.005 · Cited by 12
Self-citationAntithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 14
Tam, C. C., Chan, Y., Wong, Y., Li, Z., Zhu, X., Su, K.-J., Ganguly, A., Hwa, K., Ling, X. B., & Tse, H. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317513 · Cited by 12
Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy
Patel, H., Sharma, T., Bali, A. D., Isath, A. M., Aronow, W. S., & Haidry, S. A. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161172 · Cited by 12
“Antiplatelet therapy is the standard of care following percutaneous coronary intervention (PCI) with drug-eluting stent (DES) placement, to reduce in-stent complications such as acute thrombosis [1, 2].”
InfluentialGioscia, R., Castagno, C., Verdoia, M., Conti, B., Forliti, E., & Rognoni, A. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i4.142 · Cited by 12
Aging and Antithrombotic Treatment
Valeriani, E., Bartimoccia, S., Pignatelli, P., & Pastori, D. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0373 · Cited by 13
Antiplatelet Therapy and Anticoagulation before, during, and after Acute Coronary Syndrome
Kaufmann, C. C., Muthspiel, M., Lunzer, L., Pogran, E., Zweiker, D., Burger, A. L., Wojta, J., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082313 · Cited by 13
“Notably, bleeding rates were significantly increased when compared to aspirin monotherapy (2.5% vs. 1.6%, p = 0.001), underscoring the limitation of current recommendations for patients who do not exhibit HBR [46].”
BackgroundInfluentialCortese, B., Buccheri, D., Piraino, D., Orrego, P. S., & Seregni, R. G. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.223 · Cited by 12
Shedding blood: anemia and adverse events after percutaneous coronary intervention (PCI)
Galougahi, K. K., Karmpaliotis, D., Kirtane, A. J., & Ali, Z. A. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.02.29 · Cited by 12
Held, P., Himmelmänn, A., & Ditmarsch, M. (2016) · Future Cardiology · doi:10.2217/fca-2016-0028 · Cited by 12
Rizik, D. G., Hermiller, J. B., & Kereiakes, D. J. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26810 · Cited by 12
Self-citationCabrera-Fuentes, H. A., Lee, K., Cho, Y., Park, K., Park, T., Kim, Y., Yoon, S.-C., Serebruany, V. L., & Kim, M. H. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0971 · Cited by 12
Ki, Y., Kang, J., Park, J., Han, J., Yang, H., Park, K. W., Kang, H., Koo, B., & Kim, H.-S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030652 · Cited by 13
“Among these, the EXCELLENT [10], RESET [11], DES-LATE [12], IVUS-XPL [13], and NIPPON [14] stud es were conducte in East Asian countries (13,312 patients), while the PRODIGY [15], OPTIMIZE [16], ARCTIC INT [17], DAPT [18], SECURITY [19], ISAR-SAFE 20 , ITALIC [21], and OPTIDUAL [22] were trials performed in non–East A…”
BackgroundNovel Oral Anticoagulants Following Percutaneous Coronary Intervention
Abadie, B. Q., Cannon, C. P., & Cavender, M. A. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008465 · Cited by 12
Asami, M., Aoki, J., Sato, T., Tanimoto, S., Watanabe, M., Horiuchi, Y., Furui, K., Yasuhara, K., Sato, Y., Hashimoto, T., et al. (2016) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-016-0447-4 · Cited by 12
Cosentino, N., Campodonico, J., Faggiano, P. M., Metrio, M. D., Rubino, M., Milazzo, V., Sbolli, M., Perego, C., Provini, M., Bonomi, A., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.142 · Cited by 12
Baber, U., Leisman, D. E., Cohen, D. J., Gibson, C. M., Henry, T. D., Dangas, G., Moliterno, D. J., Kini, A. S., Krucoff, M. W., Colombo, A., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004945 · Cited by 12
Self-citationfor the J-PCI Investigators, Fujii, T., Ikari, Y., Hashimoto, H., Kadota, K., Amano, T., Uemura, S., Takashima, H., & Nakamura, M. (2019) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-019-00582-0 · Cited by 12
Ribera, A., González, I. F., Marsal, J. R., Oristrell, G., Faixedas, M. T., Rosas, A., Tizón‐Marcos, H., Rojas, S., Labata, C., Cárdenas, M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028114 · Cited by 12
Wang, H., Dou, K., Wang, Y., Yin, D., Xu, B., & Gao, R.-L. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07030-9 · Cited by 12
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?
Feng, W.-H., Hsieh, I.-C., & Li, Y.-H. (2021) · Europe PMC (PubMed Central) · doi:10.6515/acs.202101_37(1).20200806a · Cited by 12
Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes
Bates, E. (2019) · New England Journal of Medicine · doi:10.1056/nejme1910813 · Cited by 12
Otsuka, Y., Ishii, M., Ikebe, S., Nakamura, T., Tsujita, K., Kaikita, K., Matoba, T., Kohro, T., Oba, Y., Kabutoya, T., et al. (2023) · Open Heart · doi:10.1136/openhrt-2023-002489 · Cited by 11
Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes
Russo, I., Brookles, C. G., Barale, C., Melchionda, E., Mousavi, A. H., Biolè, C., Chinaglia, A., & Bianco, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073981 · Cited by 12
“Trying to answer this question, the DAPT study [106] enrolled >9000 patients and tested prolongation of DAPT with either 75 mg/die clopidogrel or 10 mg/die prasugrel for 18 months after 12-month standard therapy.”
BackgroundExtended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
Tian, J., Wang, Z., Wang, Y., Wang, F., Peng, X., Xiao, J., Li, C., Hou, X., Tong, Q., Yu, X., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2517588 · Cited by 12
Schiele, F., Puymirat, É., Bonello, L., Dentan, G., Meneveau, N., Collet, J., Motreff, P., Ravan, R., Leclercq, F., Ennezat, P., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.333 · Cited by 11
“Data from the CURE study [1] showed an increased bleeding risk with DAPT, and further randomized studies have confirmed that prolonged DAPT is associated with more bleedings [11,26,27].”
BackgroundMethodInfluentialFocused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease
Mauri, L., & Smith, S. C. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2171 · Cited by 11
Self-citationBagai, A., Wang, T. Y., Goodman, S. G., Fisher, H. N., Welsh, R. C., Déry, J., Zhang, X., Zhu, Y. E., Cheema, A. N., Dehghani, P., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.240 · Cited by 13
Villablanca, P. A., Massera, D., Mathew, V., Bangalore, S., Christia, P., Perez, I. E., Wan, N., Schüpke, S., Briceno, D. F., Bortnick, A. E., et al. (2016) · Medicine · doi:10.1097/md.0000000000005819 · Cited by 11
Caneiro‐Queija, B., Abu‐Assi, E., Raposeiras‐Roubín, S., Manzano‐Fernández, S., Blanco, P. F., López‐Cuenca, Á., Paz, R. C., Gómez-Molina, M., Rodríguez-Rodríguez, J. M., Calvo, F., et al. (2018) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.02.008 · Cited by 13
Chen, H., Power, D., & Giustino, G. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1523718 · Cited by 11
“Conversely, extension of DAPT beyond an initial mandatory period aims to protect the entire coronary vasculature from atherothrombotic events secondary to the progression of coronary atherosclerosis; therefore, preventing both stent-related and non-stent-related thrombotic events [5,28,35].”
BackgroundVerdoia, M., Kedhi, E., Suryapranata, H., Frati, G., Biondi‐Zoccai, G., & Luca, G. D. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-02033-2 · Cited by 11
Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention
Luca, L. D., & Valgimigli, M. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa107 · Cited by 12
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes
Alkhalil, M., Kuzemczak, M., Bell, A., Stern, S., Welsford, M., Cantor, W. J., & Goodman, S. G. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.202863 · Cited by 13
Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring
Gumiężna, K., Baruś, P., Sygitowicz, G., Wiśniewska, A., Ochijewicz, D., Pasierb, K., Klimczak‐Tomaniak, D., Kuca‐Warnawin, E., Kochman, J., Grabowski, M., et al. (2023) · Cardiology Journal · doi:10.5603/cj.a2023.0019 · Cited by 11
“This occurred in either, patients receiving clopidogrel, ticagrelor or prasugrel and may partly explain the increased incidence of ischemic events after the exclusion of P2Y 12 inhibitor from DAPT [37–39].”
BackgroundFaridi, K. F., Strom, J. B., Kundi, H., Butala, N. M., Curtis, J. P., Gao, Q., Song, Y., Zheng, L., Tamez, H. E., Shen, C., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029588 · Cited by 12
Self-citationThin strut bare metal stents in patients with atrial fibrillation: Is there still a need for BMS?
Leschke, M., Waliszewski, M. W., Pons, M., Champin, S., Nait-Saïdi, L., Heang, T. M., Maskon, O., Ahmad, W. A. B. W., Herberger, D., Moulichon, M. E., et al. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26261 · Cited by 11
“The recently published DAPT study [19] investigated the risk of ST beyond 12 months after stenting in two treatment groups with and without the continued use of DAPT after 1year post-PCI.”
BackgroundSwitching P2Y12 Receptor Inhibiting Therapies
Rollini, F., Franchi, F., & Angiolillo, D. J. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.006 · Cited by 11
Schoos, M. M., Chandrasekhar, J., Baber, U., Bhasin, A., Sartori, S., Aquino, M. B., Vogel, B., Farhan, S., Sorrentino, S., Kini, A. S., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.016 · Cited by 11
Self-citationPerioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel
Atay, S. M., Correa, A. M., Hofstetter, W. L., Mehran, R. J., Rice, D. C., Roth, J. A., Sepesi, B., Swisher, S. G., Vaporciyan, A. A., Walsh, G. L., et al. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.05.021 · Cited by 11
Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
Chaturvedula, S. T., Diver, D. J., & Vashist, A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040074 · Cited by 11
“DAPT [23] = Dual AntiPlatelet Therapy study, Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents; DES LATE [51] = Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation; ARCTIC INTERRUPTION [52] = Dual-antiplatelet treatment beyond 1 year after drug-eluting stent imp…”
BackgroundInfluentialDefining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation
Krumme, A. A., Glynn, R. J., Schneeweiß, S., Choudhry, N. K., Tong, A. Y., & Gagne, J. J. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004684 · Cited by 11
D’Ascenzo, F., Barbero, U., Abdirashid, M., Trabattoni, D., Boccuzzi, G. G., Ryan, N., Quadri, G., Capodanno, D., Venuti, G., Muscoli, S., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.058 · Cited by 11
Self-citationHb, W., Hp, T., Wang, X.-C., Bai, S.-R., Xn, L., Ln, Z., & Du, R. (2018) · Europe PMC (PubMed Central) · Cited by 11
Yamamoto, K., Shiomi, H., Morimoto, T., Takeji, Y., Yoshikawa, Y., Natsuaki, M., Watanabe, H., Tada, T., Tazaki, J., Yamaji, K., et al. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29335 · Cited by 11
“However, the rates of major bleeding either defined by the GUSTO moderate/severe or BARC 3 or 5 definitions were reported to be comparable in several previous studies.(1,16) Finally, collection of follow-up information was mainly conducted through review of hospital charts.”
ResultGelbenegger, G., Erari-Canyurt, U., Grafeneder, J., Jilma, B., Lesiak, M., Komosa, A., Caterina, R. D., Postula, M. A., & Siller-Matula, J. M. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106858 · Cited by 12
Lee, S. H., Lee, S. Y., Chun, W. J., Song, Y. B., Choi, S.-H., Jeong, J.-O., Oh, S. K., Yun, K. H., Koh, Y.-Y., Bae, J.-W., et al. (2021) · EuroIntervention · doi:10.4244/eij-d-21-00223 · Cited by 12
Natsuaki, M., & Kimura, T. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0751 · Cited by 11
Otaegui, I., Sucarrats, S. G., Molina, J. L. B., de Prado, A. P., Masotti-Centol, M., Carmona, M. Á., Martí, G., Bellera, N., Serra, B., Serra, V., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.04.043 · Cited by 13
Fei, Y., Tsoi, M. F., Cheung, T. T., & Cheung, B. M. Y. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.070 · Cited by 11
“DAPT 2014 [15] (NCT00977938) 9,961 30 vs.”
BackgroundResultInfluentialHusted, S. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s75024 · Cited by 11
“outcomes after the standard recommended 12 months in 9,961 patients randomly assigned to continue thienopyridine (clopidogrel or prasugrel) treatment or placebo.(61) This study found that compared with patients taking placebo, patients who continued thienopyridine treatment had reduced rates of coprimary end points, s…”
InfluentialVery very late stent thrombosis: 9.5 years after DES implantation
Gupta, S. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.01.018 · Cited by 11
“In the recent DAPT trial, more than 9000 patients with DES implantation were randomized to receive either 12 months or 30 months of DAPT.13 The primary end point of cardiac death, myocardial infarction or stroke was significantly decreased with 30 months in comparison with 12 months DAPT (4.3 vs 5.9%, p 0.001).”
MethodInfluentialAntithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., Narula, J., & Fuster, V. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.013 · Cited by 12
Bleeding events and maintenance dose of prasugrel: BLESS pilot study
Carrabba, N., Parodi, G., Marcucci, R., Valenti, R., Gori, A. M., Migliorini, A., Comito, V., Bellandi, B., Abbate, R., Gensini, G. F., et al. (2016) · Open Heart · doi:10.1136/openhrt-2016-000460 · Cited by 12
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg
Jakubowski, J. A., Erlinge, D., Alexopoulos, D. K., Small, D. S., Winters, K. J., Gurbel, P. A., & Angiolillo, D. J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0202-3 · Cited by 11
Cho, M. S., & Park, D. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.391 · Cited by 11
Westermann, D., Goodman, S. G., Nicolau, J. C., Requena, G., Maguire, A., Chen, J. Y., Granger, C. B., Grieve, R., Pocock, S., Blankenberg, S., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22837 · Cited by 11
“Studies prolonging dual antiplatelet therapy for >12 months show improved outcomes in this regard.(12,13) However, other combinations of antiplatelet drugs combined with low-dose oral anticoagulants appear to be beneficial for long-term event reduction.”
BackgroundShimamatsu, J., Sasaki, K., Katsuki, Y., Kawasaki, T., Murasato, Y., Ajisaka, H., Yokoi, H., Tashiro, H., Harada, A., Hirakawa, Y., et al. (2019) · Heart and Vessels · doi:10.1007/s00380-019-01499-7 · Cited by 12
Mühlberger, V., Kaltenbach, L., Bates, K., & Ulmer, H. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01599-4 · Cited by 11
“Maybe the application of dual antiplatelet therapy (DAPT), even in all-comers, is now proving effective [28].”
BackgroundFaridi, K. F., Tamez, H. E., Strom, J. B., Song, Y., Butala, N. M., Shen, C., Secemsky, E. A., Mauri, L., Curtis, J. P., Gibson, C. M., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047729 · Cited by 11
Self-citationYerasi, C., Case, B. C., Forrestal, B. J., Torguson, R., Weintraub, W. S., García‐García, H. M., & Waksman, R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.061 · Cited by 11
Bleeding associated with the management of acute coronary syndromes
Silva, K. D., Myat, A., Cotton, J. M., James, S. K., Gershlick, A., & Stone, G. W. (2017) · Heart · doi:10.1136/heartjnl-2015-307602 · Cited by 11
Abo‐Salem, E., Alsidawi, S., Jamali, H. K., Effat, M., & Helmy, T. A. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12137 · Cited by 10
Long-term Cardiovascular Risk After Acute Coronary Syndrome, An Ongoing Challenge
Bueno, H., & Martín‐Asenjo, R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.08.020 · Cited by 10
Riesgo cardiovascular a largo plazo tras un síndrome coronario agudo, todavía un reto
Bueno, H., & Martín‐Asenjo, R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.08.019 · Cited by 10
Qi, J., Li, Y., Li, J., Jing, Q., Xu, K., Gao, C., Ma, L., Zhang, Z., Xu, B., & Han, Y. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26947 · Cited by 12
“The DAPT trial, which enrolled either stable (38%) or unstable patients, was the largest the randomized trial to compare longer DAPT durations to shorter DAPT durations after DES placement [12].”
BackgroundChang, C. C., Onuma, Y., Achenbach, S., Barbato, E., Chevalier, B., Cook, S., Dudek, D., Escaned, J., Gori, T., Kočka, V., et al. (2019) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2019.04.013 · Cited by 10
Stub, D. A., Fernando, H., McFadyen, J. D., Palasubramaniam, J., Shaw, J. A., Wang, X., & Peter, K. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1714212 · Cited by 10
Zheng, Y., Wu, T., Guo, Q., Chen, Y., Ma, X., Ma, Y., Zhang, J., & Xie, X. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.012 · Cited by 10
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.